Outlook Therapeutics has re-submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) ...

In the United States, ONS-5010 / LYTENAVA™ (bevacizumab-vikg) is investigational.

Fintel reports that on February 28, 2025, JP Morgan downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from ...

Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) had its price target reduced by research analysts at Ascendiant Capital Markets from $33.00 to $24.00 in a research note issued to investors on ...

Research analysts at HC Wainwright lowered their Q1 2025 earnings estimates for shares of Fulcrum Therapeutics in a report released on Wednesday, February 26th. HC Wainwright analyst A. Fein now ...

On-demand video webcast now available here ISELIN, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval ...

Fintel reports that on February 27, 2025, HC Wainwright & Co. downgraded their outlook for LAVA Therapeutics N.V.

Two major players in the business email market are Google 's Gmail and Microsoft 's Outlook, as both offer a variety of ...

Jasper Therapeutics, Inc. (NASDAQ:JSPR) is a clinical-stage biotechnology company focused on developing novel therapies for hematopoietic stem cell transplantation and mast cell-mediated diseases.

The new Outlook comes bundled with the recent versions of monthly security updates. Since it’s the only free mail client on ...